Experiments and Dynamic Treatment Regimes S.A. Murphy At NIAID, BRB December, 2007.

Slides:



Advertisements
Similar presentations
Piloting and Sizing Sequential Multiple Assignment Randomized Trials in Dynamic Treatment Regime Development 2012 Atlantic Causal Inference Conference.
Advertisements

Experimental Design, Response Surface Analysis, and Optimization
Treatment Effect Heterogeneity & Dynamic Treatment Regime Development S.A. Murphy.
11 Confidence Intervals, Q-Learning and Dynamic Treatment Regimes S.A. Murphy Time for Causality – Bristol April, 2012 TexPoint fonts used in EMF. Read.
Using Clinical Trial Data to Construct Policies for Guiding Clinical Decision Making S. Murphy & J. Pineau American Control Conference Special Session.
Experimenting to Improve Clinical Practice S.A. Murphy AAAS, 02/15/13 TexPoint fonts used in EMF. Read the TexPoint manual before you delete this box.:
1 Developing Dynamic Treatment Regimes for Chronic Disorders S.A. Murphy Univ. of Michigan RAND: August, 2005.
1 Dynamic Treatment Regimes Advances and Open Problems S.A. Murphy ICSPRAR-2008.
1 Developing Adaptive Treatment Strategies using MOST Experimental Designs S.A. Murphy Univ. of Michigan Dallas: December, 2005.
Methodology for Adaptive Treatment Strategies for Chronic Disorders: Focus on Pain S.A. Murphy NIH Pain Consortium 5 th Annual Symposium on Advances in.
Experiments and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan JSM: August, 2005.
SMART Designs for Constructing Adaptive Treatment Strategies S.A. Murphy 15th Annual Duke Nicotine Research Conference September, 2009.
Dynamic Treatment Regimes, STAR*D & Voting D. Lizotte, E. Laber & S. Murphy LSU ---- Geaux Tigers! April 2009.
Substance Abuse, Multi-Stage Decisions, Generalization Error How are they connected?! S.A. Murphy Univ. of Michigan CMU, Nov., 2004.
An Experimental Paradigm for Developing Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan March, 2004.
Constructing Dynamic Treatment Regimes & STAR*D S.A. Murphy ICSA June 2008.
Screening Experiments for Developing Dynamic Treatment Regimes S.A. Murphy At ICSPRAR January, 2008.
SMART Designs for Developing Adaptive Treatment Strategies S.A. Murphy K. Lynch, J. McKay, D. Oslin & T.Ten Have CPDD June, 2005.
Dynamic Treatment Regimes: Challenges in Data Analysis S.A. Murphy Survey Research Center January, 2009.
Q-Learning and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan IMS/Bernoulli: July, 2004.
1 A Prediction Interval for the Misclassification Rate E.B. Laber & S.A. Murphy.
Sizing a Trial for the Development of Adaptive Treatment Strategies Alena I. Oetting The Society for Clinical Trials, 29th Annual Meeting St. Louis, MO.
Screening Experiments for Dynamic Treatment Regimes S.A. Murphy At ENAR March, 2008.
Experiments and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan Florida: January, 2006.
SMART Experimental Designs for Developing Adaptive Treatment Strategies S.A. Murphy NIDA DESPR February, 2007.
Hypothesis Testing and Dynamic Treatment Regimes S.A. Murphy Schering-Plough Workshop May 2007 TexPoint fonts used in EMF. Read the TexPoint manual before.
Michigan Team February, Amy Wagaman Bibhas Chakraborty Herle McGowan Susan Murphy Lacey Gunter Danny Almirall Anne Buu.
An Experimental Paradigm for Developing Adaptive Treatment Strategies S.A. Murphy Univ. of Michigan UNC: November, 2003.
1 A Confidence Interval for the Misclassification Rate S.A. Murphy & E.B. Laber.
Experiments and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan PSU, October, 2005 In Honor of Clifford C. Clogg.
Planning Survival Analysis Studies of Dynamic Treatment Regimes Z. Li & S.A. Murphy UNC October, 2009.
Statistical Issues in Developing Adaptive Treatment Strategies for Chronic Disorders S.A. Murphy Univ. of Michigan CDC/ATSDR: March, 2005.
SMART Experimental Designs for Developing Adaptive Treatment Strategies S.A. Murphy RWJ Clinical Scholars Program, UMich April, 2007.
Hypothesis Testing and Dynamic Treatment Regimes S.A. Murphy, L. Gunter & B. Chakraborty ENAR March 2007.
1 SMART Designs for Developing Adaptive Treatment Strategies S.A. Murphy K. Lynch, J. McKay, D. Oslin & T.Ten Have UMichSpline February, 2006.
Dynamic Treatment Regimes, STAR*D & Voting D. Lizotte, E. Laber & S. Murphy ENAR March 2009.
A Finite Sample Upper Bound on the Generalization Error for Q-Learning S.A. Murphy Univ. of Michigan CALD: February, 2005.
Methodology for Adaptive Treatment Strategies R21 DA S.A. Murphy For MCATS Oct. 8, 2009.
An Experimental Paradigm for Developing Adaptive Treatment Strategies S.A. Murphy Univ. of Michigan ACSIR, July, 2003.
Dynamic Treatment Regimes, STAR*D & Voting D. Lizotte, E. Laber & S. Murphy Psychiatric Biostatistics Symposium May 2009.
An Experimental Paradigm for Developing Adaptive Treatment Strategies S.A. Murphy Univ. of Michigan February, 2004.
Experiments and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan Yale: November, 2005.
Methods for Estimating the Decision Rules in Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan IBC/ASC: July, 2004.
1 Possible Roles for Reinforcement Learning in Clinical Research S.A. Murphy November 14, 2007.
Experiments and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan April, 2006.
SMART Designs for Developing Dynamic Treatment Regimes S.A. Murphy MD Anderson December 2006.
SMART Experimental Designs for Developing Adaptive Treatment Strategies S.A. Murphy ISCTM, 2007.
1 A Prediction Interval for the Misclassification Rate E.B. Laber & S.A. Murphy.
Experiments and Adaptive Treatment Strategies S.A. Murphy Univ. of Michigan Chicago: May, 2005.
1 Dynamic Treatment Regimes: Interventions for Chronic Conditions (such as Poverty or Criminality?) S.A. Murphy Univ. of Michigan In Honor of Clifford.
SMART Designs for Developing Dynamic Treatment Regimes S.A. Murphy Symposium on Causal Inference Johns Hopkins, January, 2006.
1 Machine/Reinforcement Learning in Clinical Research S.A. Murphy May 19, 2008.
Adaptive Treatment Strategies S.A. Murphy CCNIA Proposal Meeting 2008.
Adaptive Treatment Strategies S.A. Murphy Workshop on Adaptive Treatment Strategies Convergence, 2008.
Practical Application of Adaptive Treatment Strategies in Trial Design and Analysis S.A. Murphy Center for Clinical Trials Network Classroom Series April.
Experiments and Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan January, 2006.
Hypothesis Testing and Adaptive Treatment Strategies S.A. Murphy SCT May 2007.
Adaptive Treatment Design and Analysis S.A. Murphy TRC, UPenn April, 2007.
Adaptive Treatment Strategies: Challenges in Data Analysis S.A. Murphy NY State Psychiatric Institute February, 2009.
Sequential, Multiple Assignment, Randomized Trials and Treatment Policies S.A. Murphy UAlberta, 09/28/12 TexPoint fonts used in EMF. Read the TexPoint.
Sequential, Multiple Assignment, Randomized Trials and Treatment Policies S.A. Murphy MUCMD, 08/10/12 TexPoint fonts used in EMF. Read the TexPoint manual.
Engineering Statistics ENGR 592 Prepared by: Mariam El-Maghraby Date: 26/05/04 Design of Experiments Plackett-Burman Box-Behnken.
Sequential, Multiple Assignment, Randomized Trials Module 2—Day 1 Getting SMART About Developing Individualized Adaptive Health Interventions Methods Work,
1 SMART Designs for Developing Adaptive Treatment Strategies S.A. Murphy K. Lynch, J. McKay, D. Oslin & T.Ten Have NDRI April, 2006.
Simulation Study for Longitudinal Data with Nonignorable Missing Data Rong Liu, PhD Candidate Dr. Ramakrishnan, Advisor Department of Biostatistics Virginia.
Motivation Using SMART research designs to improve individualized treatments Alena Scott 1, Janet Levy 3, and Susan Murphy 1,2 Institute for Social Research.
An Experimental Paradigm for Developing Adaptive Treatment Strategies S.A. Murphy NIDA Meeting on Treatment and Recovery Processes January, 2004.
Designing An Adaptive Treatment Susan A. Murphy Univ. of Michigan Joint with Linda Collins & Karen Bierman Pennsylvania State Univ.
SMART Trials for Developing Adaptive Treatment Strategies S.A. Murphy Workshop on Adaptive Treatment Designs NCDEU, 2006.
Designs for Experiments with More Than One Factor When the experimenter is interested in the effect of multiple factors on a response a factorial design.
Presentation transcript:

Experiments and Dynamic Treatment Regimes S.A. Murphy At NIAID, BRB December, 2007

2 Outline Dynamic Treatment Regimes Challenges in Experimentation Defining Effects and Aliasing Example

3 Dynamic treatment regimes are individually tailored treatments, with treatment type and dosage changing with ongoing subject need. Mimic Clinical Practice. High variability across patients in response to any one treatment Relapse is likely without either continuous or intermittent treatment for a large proportion of people. What works now may not work later Exacerbations in disorder may occur if there are no alterations in treatment

4 The Big Questions What is the best sequencing of treatments? What is the best timings of alterations in treatments? What information do we use to make these decisions?

5 Two stages of treatment for each individual Observation available at j th stage Treatment (vector) at j th stage Primary outcome Y is a specified summary of decisions and observations

6 A dynamic treatment regime is a vector of decision rules, one per decision where each decision rule inputs the available information and outputs a recommended treatment decision.

7 Challenges in Experimentation

8 Dynamic Treatment Regimes (review) Constructing decision rules is a multi-stage decision problem in which the system dynamics are unknown. High quality data is likely provided by sequential multiple assignment randomized trials: randomize at each decision point— à la full factorial.

9 ExTENd Ongoing study at U. Pennsylvania (D. Oslin) Goal is to learn how best to help alcohol dependent individuals reduce alcohol consumption.

10 Oslin ExTENd Late Trigger for Nonresponse 8 wks Response TDM + Naltrexone CBI Random assignment: CBI +Naltrexone Nonresponse Early Trigger for Nonresponse Random assignment: Naltrexone 8 wks Response Random assignment: CBI +Naltrexone CBI TDM + Naltrexone Naltrexone Nonresponse

11 Challenges in Experimentation Dynamic Treatment Regimes are multi-component treatments: many possible components decision options for improving patients are often different from decision options for non-improving patients (T 2 is a vector and differs by outcomes observed during initial treatment) multiple components employed simultaneously medications, behavioral therapy, adjunctive treatments, delivery mechanisms, motivational therapy, staff training, monitoring schedule……. Future: series of screening/refining, randomized trials prior to confirmatory trial --- à la Fisher/Box

12 Screening experiments (review) 1)Goal is to eliminate inactive factors (e.g. components) and inactive effects. 2)Each factor at 2 levels 3)Screen main effects and some interactions 4)Design experiment using working assumptions concerning the negligibility of certain higher order factorial effects. 5)Designs and analyses permit one to determine aliasing (caused by false working assumptions) 6)Minimize formal assumptions

13 Stage 1 Factors: T 1 ={ A, B, C, D}, each with 2 levels Stage 1 outcome: Stage 2 Factors: T 2 = {F 2 --only if R=1, G 2 —only if R=0}, each with 2 levels Primary Outcome: Y continuous (2 6 = 64 simple dynamic treatment regimes) Simple Example for Two Stages

14 Two Stage Design: I=ABCDF 2 =ABCDG 2 A B C D F 2 =G

15 Screening experiments Can we: design screening experiments using working assumptions concerning higher order effects & determine the aliasing and provide an analysis method?

16 Defining the Effects

17 Reality

18 Defining the stage 2 effects Simple case: two stages of treatment with only one factor at each stage, a early measure of response, R at the end of stage 1 and a primary outcome Y. The potential outcomes are Define effects involving T 2 in a saturated linear model for

19 Defining the stage 2 effects Suppose the factors T 1 and T 2 are randomized. Assume consistency (Robins, 1997) then

20 Defining the stage 2 effects Define (factorial) effects involving T 2 in a saturated linear model

21 Defining the stage 2 effects

22 Defining the stage 1 effects (T 1 )

23 Defining the stage 1 effects

24 Defining the stage 1 effects Define effects involving only T 1 in a saturated linear model The above is equal to when {T 1, T 2 } are randomized and T 2 has a discrete uniform distribution on {-1,1}.

25 Defining the stage 1 effects In general when {T 1, T 2 } are randomized

26 Why marginal, why uniform? Define effects involving only T 1 via 1)The defined effects are causal. 2)The defined effects are consistent with tradition in experimental design for screening. –The main effect for one treatment factor is defined by marginalizing over the remaining treatment factors using a discrete uniform distribution.

27 Surprisingly both stage 1 and 2 effects can be represented in one (nonstandard) linear model: Representing the effects

28 where Causal effects: Nuisance parameters: and

29 Two Stage Design: I=ABCDF 2 =ABCDG 2 A B C D F 2 =G

30 General Formula Saturated model (for both R=0, 1) Z 1 matrix of stage 1 factor columns, Z 2 is the matrix of stage 2 factor columns, Y is a vector, p is the vector of response rates Classical saturated factorial effects model

31 Aliasing

32 Aliasing (Identification of Effects) In classical designs, the defining words immediately yield the aliasing. For example I=ABCDF means that only the sum of the main effect of F and the four way interaction, ABCD can be identified. The two effects can not be separately estimated. We can do the same here with a caveat.

33 Aliasing (Identification of Effects) The rows of {Z 1, Z 2 } are determined by the experimental design; each column in Z 1 is associated with a stage 1 factorial effect and similarly each column in Z 2 is associated with a stage 2 factorial effect. Fractional factorial designs lead to common columns in {Z 1, Z 2 }; these columns are given by the defining words.

34 Aliasing (Identification of Effects) Consider designs for which the defining words indicate a shared column in both Z 1 and Z 2 only if the column in Z 1 can be safely assumed to have a zero η coefficient or if the column in Z 2 can be safely assumed to have a zero β, α coefficient. The defining words then provide the aliasing in this case.

35 Six Factors: Stage 1: T 1 ={ A, B, C, D}, each with 2 levels Stage 2: T 2 = {F 2 --only for stage 1 responders, G 2 --only for stage 1 nonresponders}, each with 2 levels (2 6 = 64 simple dynamic treatment regimes) Simple Example for Two Stages

36 Two Stage Design: I=ABCDF 2 =ABCDG 2 A B C D F 2 =G

37 Simple Example This design has defining words: 1=ABCDF 2 =ABCDG 2 The labels of the identical columns in Z 1, Z 2 are CD=ABG 2, ABC=DG 2, F 2 DC=AB………..

38 Formal Assumptions for this Design We use this design if we can assume that all three way and higher order stage 2 effects are negligible (ABG 2, ABF 2, ABCG 2, ABCF 2, ….)—these are all β and α parameters. assume all four way and higher order effects involving R and stage 1 factors are negligible (R- p)ABCD, (R-p)ABC, (R-p)ABD …--- these are all η parameters. 1=ABCDF 2 =ABCDG 2

39 Aliasing for this Design Stage 1 main effects and stage 2 four-way interactions are aliased (e.g. A=BCDF 2, etc.). Stage 1 two way interactions and stage 2 three way interactions are aliased (e.g. CD=ABG 2, AB=CDF 2, etc.) Stage 1 three way interactions and stage 2 two way interactions are aliased (e.g. ABC=DF 2, ABC=DG 2, etc.) The Stage 1 four way interaction and stage 2 main effects are aliased (e.g. ABCD=F 2, ABCD=G 2 ). 1=ABCDF 2 =ABCDG 2

40 Working Assumptions for this Design Stage 2 three-way and four-way interactions are negligible. Stage 1 three-way and four-way interactions are negligible. If the working assumptions are correct then we will be able to estimate the “non-aliased” main and two-way interactions for both stage 1 and stage 2.

41 Analysis for this design Recall that Many columns in Z 1, Z 2 are identical (hence the aliasing of effects). Eliminate all multiple copies of columns and label remaining columns as stage 1 (or stage 2) main and two-way interaction effects. Replace response rates in p by observed response rates. Fit model.

42 Interesting Result in Simulations In simulations formal assumptions are violated. Response rates (probability of R=1) across 16 cells range from.55 to.73 Results are surprisingly robust to violations of formal assumptions. The maximal value of the correlation between 32 estimators of effects was.12 and average absolute correlation value is.03 Why? Binary R variables can not vary that much. If response rate is constant, then the effect estimators are uncorrelated as in classical experimental design.

43 Discussion Compare this to using observational studies to construct dynamic treatment regimes –Uncontrolled selection bias (causal misattributions) –Uncontrolled aliasing. Secondary analyses would assess if other variables collected during treatment should enter decision rules.

44 Joint work with –Derek Bingham (Simon Fraser) And informed by discussions with –Vijay Nair (U. Michigan) –Bibhas Chakraborty (U. Michigan) –Vic Strecher (U. Michigan) This seminar can be found at: lsa.umich.edu/~samurphy/seminars/NIAID12.07.ppt